Get the Stockscreener App
29.04
1.49%
-0.44
After Hours:
29.44
0.40
+1.38%
Ideaya Biosciences Inc stock is traded at $29.04, with a volume of 770.02K.
It is down -1.49% in the last 24 hours and down -4.66% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$29.48
Open:
$29.82
24h Volume:
770.02K
Relative Volume:
0.67
Market Cap:
$2.55B
Revenue:
$218.71M
Net Income/Loss:
$-113.70M
P/E Ratio:
-22.28
EPS:
-1.3034
Net Cash Flow:
$-73.47M
1W Performance:
-8.77%
1M Performance:
-4.66%
6M Performance:
-12.50%
1Y Performance:
+47.04%
1-Day Range:
$29.02
$30.23
1-Week Range:
$29.02
$32.22
52-Week Range:
$16.82
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
29.04 | 2.59B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation - MSN
IDEAYA Biosciences Advances Precision Oncology with AI Discovery - HarianBasis.co
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout - Yahoo Finance
IDYA Price Today: IDEAYA Biosciences, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
IDYA (IDEAYA Biosciences Inc.) posts narrower than expected Q4 2025 loss, shares rise 4.31 percent.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
IDYA (IDEAYA Biosciences Inc.) reports narrower Q4 2025 loss than projections, but stock dips slightly in today's trading.Pro Level Trade Signals - Xã Thanh Hà
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - MSN
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel - BioSpace
IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation - simplywall.st
IDEAYA to present trial data at ASCO meeting in June By Investing.com - Investing.com Australia
IDEAYA to present trial data at ASCO meeting in June - Investing.com
Trading the Move, Not the Narrative: (IDYA) Edition - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5%Here's Why - MarketBeat
Why IDEAYA Biosciences Stock Is Suddenly Sinking - TipRanks
IDEAYA gets late-breaking ASCO slot for full uveal melanoma data - Stock Titan
Is IDEAYA Biosciences (IDYA) stock risky for investors (Builds on Momentum) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
IDEAYA Biosciences Inc : JP Morgan Raises Tar - Moomoo
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5%Should You Sell? - MarketBeat
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars - Sahm
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Tudor Investment Corp ET AL Purchases New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Yahoo Finance
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - The Malaysian Reserve
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal MelanomaSlideshow (NASDAQ:IDYA) 2026-04-13 - Seeking Alpha
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
Oppenheimer raises Ideaya Biosciences price target on trial data By Investing.com - Investing.com Canada
Ideaya Biosciences: Stock Buoyant On Good mUM DataBut Approval Not A Formality - Seeking Alpha
Truist raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA) Stock Jumps 26% After Eye Cancer Trial Blows Past Standard Care - MEXC Exchange
IDEAYA’s uveal melanoma drug combo meets trial goals By Investing.com - Investing.com Australia
Goldman Sachs raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
Goldman Sachs raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap UpTime to Buy? - MarketBeat
Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why. - Barron's
Ideaya Biosciences (IDYA) Sees Significant Surge in Stock Price - GuruFocus
IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data - MEXC Exchange
IDEAYA Biosciences Inc - Reuters
IDEAYA Surges After Positive Data From Phase2/3 OptimUM-02 Trial Of Darovasertib In MUM - RTTNews
IDYA: Darovasertib plus crizotinib doubled PFS and improved ORR in HLA-A*02:01-negative mUM - TradingView
IDEAYA Biosciences stock surges 27% on trial results - Investing.com
IDEAYA Biosciences stock surges 27% on trial results By Investing.com - Investing.com UK
IDEAYA’s uveal melanoma drug combo meets trial goals - Investing.com
IDEAYA Biosciences' darovasertib+crizotinib cuts progression risk 58%, median PFS 6.9 vs 3.1 months - TradingView
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):